

### CANCER

- NICE no longer recommends looking for an occult Ca in unprovoked VTE.
- Ensure bloods (FBC, renal function, LFTs, PT, APPT).
- Hx and examination for obvious signs of Ca.
- Commonest Ca = urogenital, breast, colorectal and lung.
- Why the change?
- Need 91 CT abdo/pelvic to detect 1 extra cancer compared with simple tests alone.
- For every 460 500 CT's you do, you cause 1 cancer.

### THROMBOPHILIA

- Thrombophilia screening if unprovoked VTE and 1o relative with VTE, but only if the plan is NOT to take lifelong prophylaxis.
- Why only them?
- Because screening is unnecessary if pt will remain on prophylaxis OR if it was obviously provoked e.g. tibia #.


### DURATION

- Unprovoked VTE = treat for min 3/12, but then specialist to decide if needed lifelong due to risks of recurrence.
- Haematology consultant advice 25/11/21:  
- Treat for 6/12, then d/w pt. If no risk factors and pt happy to take small risk of another blood clot, then stop NOAC.

Cumulative risk after stopping treatment:

- 1st yr = 10% recurrence rate, 0.4 deaths per 100 pt.
- 2nd yr = 16%, 0.7
- 5th yr = 25%, 1
- 10th yr = 36%, 1.5

- Provoked VTE = 3/12 then stop, providing the provoking factor gone.



### POST THROMBOTIC SYNDROME

- NICE no longer recommends compression hosiery.
- Why the change? No difference of placebo.
- But can still refer to vascular team for them to try to help e.g. unblock and stent blocked veins.
- So if swollen leg for > 1/12 then refer.

- Chronic pain.
- Leg swelling.
- Heaviness.
- Oedema.
- Skin changes.
- Lipodermatosclerosis.
- Ulceration.

### TREATMENT FAILURE

- Check adherence.
- Any other sources of hypercoagulability?
- ↑ dose of anticoagulant or change to one with a different mode of action.

### SUPERFICIAL THROMBOPHLEBITIS

- So the superficial veins drain into the deep veins so you must think of DVT even if you are diagnosing superficial thrombophlebitis.
- Put black marker over redness.
- If the redness is moving significantly above the mark tell the pt to come back.
- And if they do, then refer for DVT.
- If the redness is shrinking then no concerns.

### ANTICOAGULANTS

- The 3 options are LMWH, warfarin and NOAC.
- Nearly every pt should get a NOAC.
- Apixaban and Rivaroxaban are 1st line NOACs.
- Special cases below.
- Renal impairment:  
- See if NOAC can be used with their CrCl.  
- LMWH concurrently with warfarin for 5/7, or until INR ≥ 2 for 2 consecutive readings, followed by warfarin alone. If CrCl < 15, can also use LMWH alone.
- Triple positive antiphospholipid syndrome:  
- LMWH concurrently with warfarin for 5/7, or until INR ≥ 2 for 2 consecutive readings, followed by warfarin alone.
- Active cancer:  
- i.e. receiving active antimitotic treatment; or Dx past 6/12, or recurrent or metastatic, or inoperable. Excludes SCC and BCC.  
- Previously concerns about using NOAC in terms of them not being effective, but now fine to use. Alternatively LMWH or warfarin.  
- Duration is 3-6/12 rather than the min 3/12 for other pt's.

#### Apixaban

10mg BD for 7/7  
THEN  
5mg BD

After 6/12 if still needing, 2.5mg BD.

- CrCl < 15ml/min = contraindicated.

#### Dabigatran

After at least 5 days of parenteral anticoagulation  
150mg BD for duration of treatment.

\*Reduce dose to 110mg BD if any following:  
- >80y  
- Verapamil.  
- CrCl 30-50ml/min.  
- Gastritis/oesophagitis/GORD.

- CrCl < 30ml/min = contraindicated.

#### Edoxaban

After at least 5 days of parenteral anticoagulation  
60mg OD for 3/52 for duration of treatment.

\*Reduce dose to 30mg OD if any following:  
- ≤ 60kg  
- Erythromycin, ciclosporin, ketoconazole, dronedarone.  
- CrCl 15-50ml/min.  
- Gastritis/oesophagitis/GORD.

- CrCl < 15ml/min = contraindicated.

#### Rivaroxaban

15mg BD for 21/7.  
THEN  
20mg OD (\*15mg OD if CrCl 30-50)

After 6/12 if still needing, 10mg OD, but if high risk of recurrence 20mg OD (\*15mg OD if CrCl 30-50)

- CrCl < 15ml/min = contraindicated.

- Monitor UEs to calculate CrCl:  
- If CrCl > 60 annual UEs.  
- If CrCl 30-60, measure UEs every 6/12.  
- If latest CrCl < 30, measure UEs every 3/12.  
- FBC, LFTs every yr.
- Be aware calculating CrCl if obese.  
- Use MD Calc (online calculator).
- Use the following as a guide:  
a) BMI < 18.5 - < 30 = calculate CrCl using actual body weight (box 1)  
b) BMI ≥ 30 = calculate CrCl using ideal and actual body weight, which will produce a lower and upper boundary (box 2).
- If the difference crosses over a NOAC dosing threshold, then assess bleeding and thrombosis risk to decide on suitable dose.

Liver function:  
- Elevated liver enzymes (ALT/AST >2x ULN OR total bilirubin >1.5 ULN) consider switching to warfarin.

Full blood count:  
- ↓ in Hb and/or haematocrit may suggest occult bleeding and may require further investigations.

**MD CALC**

### Creatinine Clearance (Cockcroft-Gault Equation) ☆

Sex	Female	Male
Age	74	years
Weight	87	kg
Creatinine	165	µmol/L
Height	165	cm

The Cockcroft-Gault Equation may be inaccurate depending on a patient's body weight and BMI, by providing additional height, we can calculate BMI and provide a modified estimate and range.

Box 1

43

mL/min  
Creatinine clearance, original Cockcroft-Gault

Box 2

35

mL/min  
Creatinine clearance modified for overweight patient, using adjusted body weight of 72 kg (158 lbs).

30.2-35.2

mL/min  
Note: This range uses IBW and adjusted body weight. Controversy exists over which form of weight to use.